Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis
Gro Owren Nygaard, Hilde Marie Torgauten, Lars Skattebøl, Einar August Høgestøl, Piotr Sowa, Kjell‐Morten Myhr, Øivind Torkildsen, Elisabeth Gulowsen Celius
Topics & Concepts
CladribineMedicineFingolimodRituximabMultiple sclerosisInternal medicineOncologyGastroenterologyImmunologyLymphomaMultiple Sclerosis Research StudiesPeripheral Neuropathies and DisordersPolyomavirus and related diseases